217 results on '"Ollila, Thomas A."'
Search Results
2. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
3. Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
4. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
5. Evaluation of a summer program for minority high school students in the clinical cancer center: The Future Gen Cancer Scholars program.
6. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
7. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
8. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
9. Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis.
10. Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study
11. Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects.
12. Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
13. ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
14. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease
15. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers
16. Reassessing the risks and benefits of COVID-19 precautions in 2023
17. Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
18. Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
19. Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Treated with Immunochemotherapy or Chemotherapy Alone: Analysis of the National Cancer Data Base 2013-2018
20. Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
21. Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
22. Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia
23. Poster: ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
24. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL
25. Chapter 156 - The Spleen and Its Disorders
26. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence
27. Seroconversion and outcomes after initial and booster COVID ‐19 vaccination in adults with hematologic malignancies
28. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence.
29. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
30. 62 - Otros tumores sólidos (cabeza y cuello, sarcoma, melanoma, primario de origen desconocido)
31. 62 - Other Solid Tumors (Head and Neck, Sarcomas, Melanoma, Unknown Primary)
32. Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
33. CDKN2A Deletions Define an Unfavorable Subgroup within the MYD88/CD79B (MCD) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) and Are Mutually Exclusive with TP53 mutations
34. Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices
35. Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy
36. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
37. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
38. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
39. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
40. Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma
41. Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection
42. A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma
43. EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort
44. Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era
45. Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia.
46. Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation.
47. Contributors
48. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
49. Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study
50. Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.